MDT

101.85

+2.05%↑

A

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

MDT

101.85

+2.05%↑

A

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

MDT

101.85

+2.05%↑

A

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

MDT

101.85

+2.05%↑

A

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

MDT

101.85

+2.05%↑

A

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

Search

Sanofi

Открыт

46.65 1.68

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

45.79

Макс.

46.84

Ключевые показатели

By Trading Economics

Доход

-1.1B

2.8B

Продажи

2.4B

13B

P/E

Средняя по отрасли

15.326

89.037

Рентабельность продаж

21.276

Сотрудники

82,878

EBITDA

2.3B

4.2B

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+71.43% upside

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-10B

113B

Предыдущая цена открытия

44.97

Предыдущая цена закрытия

46.65

Техническая оценка

By Trading Central

Уверенность

Strong Bearish Evidence

Sanofi График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

24 дек. 2025 г., 11:40 UTC

Приобретения, слияния, поглощения

Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal -- Update

24 дек. 2025 г., 11:17 UTC

Главные движущие силы рынка
Приобретения, слияния, поглощения

Dynavax Shares Leap Premarket on Takeover by Sanofi

24 дек. 2025 г., 06:55 UTC

Приобретения, слияния, поглощения

Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal

15 дек. 2025 г., 10:11 UTC

Главные движущие силы рынка

Sanofi Shares Fall After Multiple Sclerosis Drug Gets Hit by Double Setback

24 окт. 2025 г., 08:29 UTC

Отчет

Sanofi Earnings Get Boost From Dupixent, New Drugs as U.S. Talks Continue -- Update

16 янв. 2026 г., 17:03 UTC

Обсуждения рынка

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16 янв. 2026 г., 16:32 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

12 янв. 2026 г., 19:24 UTC

Приобретения, слияния, поглощения

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12 янв. 2026 г., 19:22 UTC

Приобретения, слияния, поглощения

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

31 дек. 2025 г., 08:49 UTC

Обсуждения рынка

Sanofi's Pipeline Weakness Likely to Hamper Growth -- Market Talk

24 дек. 2025 г., 17:08 UTC

Приобретения, слияния, поглощения

This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 дек. 2025 г., 12:59 UTC

Приобретения, слияния, поглощения

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 дек. 2025 г., 06:41 UTC

Приобретения, слияния, поглощения

Correct: Sanofi: Deal Expected to Have No Impact on 2025 Guidance

24 дек. 2025 г., 06:19 UTC

Приобретения, слияния, поглощения

Sanofi: Acquisition to Close in 1Q of 2026

24 дек. 2025 г., 06:19 UTC

Приобретения, слияния, поглощения

Sanofi: Deal Expected to Have on Impact on 2025 Guidance

24 дек. 2025 г., 06:19 UTC

Приобретения, слияния, поглощения

Sanofi: Offering $15.50 a Share in Cash for Dynavax

24 дек. 2025 г., 06:18 UTC

Приобретения, слияния, поглощения

Sanofi to Start Cash Tender Offer at Equity Value of $2.2B

24 дек. 2025 г., 06:18 UTC

Приобретения, слияния, поглощения

Sanofi: Deal Adds Marketed Adult Hepatitis B Vaccine, Phase 1/2 Shingles Candidate

24 дек. 2025 г., 06:17 UTC

Приобретения, слияния, поглощения

Sanofi to Buy Vaccine Company Dynavax Technologies

24 дек. 2025 г., 06:16 UTC

Приобретения, слияния, поглощения

Sanofi to Buy Dynavax

24 дек. 2025 г., 06:15 UTC

Приобретения, слияния, поглощения

Press Release: Sanofi To Acquire Dynavax, Adding A Marketed Adult Hepatitis B Vaccine And Phase 1/2 Shingles Candidate To The Pipeline >SAN.FR

15 дек. 2025 г., 15:03 UTC

Обсуждения рынка

Sanofi Multiple Sclerosis Trial Failure Leaves FDA Approval in Doubt -- Market Talk

15 дек. 2025 г., 13:59 UTC

Популярные акции

Stocks to Watch Monday: iRobot, Tilray, EchoStar, Juventus -- WSJ

15 дек. 2025 г., 11:18 UTC

Обсуждения рынка

Sanofi's Multiple Sclerosis Drug Fails Late-Stage Trial; Latest Pipeline Setback -- Market Talk

15 дек. 2025 г., 09:53 UTC

Популярные акции

Stocks to Watch Monday: iRobot, EchoStar, Rocket Lab, Alibaba -- WSJ

4 дек. 2025 г., 10:02 UTC

Приобретения, слияния, поглощения

Sanofi Completes Acquisition of Vicebio

4 дек. 2025 г., 10:01 UTC

Приобретения, слияния, поглощения

Sanofi Buys Vicebio

4 дек. 2025 г., 10:00 UTC

Приобретения, слияния, поглощения

Sanofi Completes Acquisition Of Vicebio >SAN.FR

24 окт. 2025 г., 08:21 UTC

Обсуждения рынка
Отчет

Sanofi Results Reflect Improved Efficiency, Should Ease Margin Worries -- Market Talk

24 окт. 2025 г., 07:56 UTC

Обсуждения рынка
Отчет

Sanofi's Dupixent Drives Growth, But Lantus Gains Set to Fade -- Market Talk

Сравнение c конкурентами

Изменение цены

Sanofi Прогноз

Целевая цена

By TipRanks

71.43% рост

Прогноз на 12 месяцев

Средняя 78.41 USD  71.43%

Максимум 116.22 USD

Минимум 57 USD

Основано на мнении 5 аналитиков Wall Street, спрогнозировавших целевые цены для Sanofi на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

5 ratings

2

Покупка

3

Удержание

0

Продажа

Техническая оценка

By Trading Central

51.665 / 52.38Поддержка и Сопротивление

Краткосрочная

Strong Bearish Evidence

Среднесрочная

Weak Bullish Evidence

Долгосрочная

Bullish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
help-icon Live chat